Celgene Corporation (CELG)

94.30
NASDAQ
Prev Close 94.55
Day Low/High 93.97 / 94.77
52 Wk Low/High 58.59 / 95.44
Exchange NASDAQ
Shares Outstanding 702.45B
Market Cap 66.42B
Div & Yield N.A. (N.A)
Possible Biotech Takeout Plays

Possible Biotech Takeout Plays

A look at possible second-quarter M&A activity in the biotech sector.

Markets Struggle to Find Direction

Markets continue to meander between being slightly up or slightly down as equities struggle for a direction after yesterday's big slide. New homes sales for the month of February were above expectations with the average selling price 10% above the s...

Celgene Showing a Bullish Divergence But Is Still In a Downtrend

Celgene Showing a Bullish Divergence But Is Still In a Downtrend

Let's check the charts.

Which Hot Biotech Name Will Be Acquired Next?

Which Hot Biotech Name Will Be Acquired Next?

Your burning biotech questions answered in our latest mailbag.

Bret Jensen's Biotech Mailbag

Bret Jensen's Biotech Mailbag

We'll answer two of the common questions we have received so far in March.

3 Promising Biotech Stocks to Buy on Dips

3 Promising Biotech Stocks to Buy on Dips

From ANI Pharmaceuticals to T2 Biosystems, these names look good.

Three Biotech Opportunities

Three Biotech Opportunities

Celgene, ANI and T2 are seeing attractive entry points.

Multiple Creep... and More

Recently I have noticed some of Wall Street's younger analysts engaging in "multiple creep." They seem to be treating a 12 EBITD (cash flow) multiple like a 12 PE (price to earnings) ratio. Whoops! No problem, for example, paying 25x EPS for ....Unt...

Three Stocks That Have My Attention

Three Stocks That Have My Attention

I continue to deploy some of the 'dry powder' into the market after its recent hiccup.

Cramer: 10 Stock Surprises

Cramer: 10 Stock Surprises

In this tape, weakness may just be a sign of rest and better times to come.

These 2 Biotech Stocks Still Have Upside

These 2 Biotech Stocks Still Have Upside

The biotech sector has seen a big rally, but there are still opportunities.

Tax Reform's Impact on the Economy

Tax Reform's Impact on the Economy

Consumer spending should be more than solid given wage increases.

Closing Bell: LIVE MARKETS BLOG

Closing Bell: LIVE MARKETS BLOG

All three indices closed the day in record territory.

Video: Jim Cramer on the Eagles, Celgene, Juno Therapeutics and Netflix

Video: Jim Cramer on the Eagles, Celgene, Juno Therapeutics and Netflix

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts to Monday's trending topics.

Video: Jim Cramer Reacts to Celgene's Plans to Acquire Juno Therapeutics

Video: Jim Cramer Reacts to Celgene's Plans to Acquire Juno Therapeutics

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts to Celgene's plans to acquire Juno Therapeutics for about $9 billion on Monday.

A Government Shutdown Won't Crush Stock Market, a New England Patriots Win Will

A Government Shutdown Won't Crush Stock Market, a New England Patriots Win Will

Another New England Patriots win in the Super Bowl could mean bad things for the stock market. What government shutdown?

M&A Rumors Rise Again

About a half hour to go before the markets open for the last trading day of the week. Acorda Therapeutics is up more than 10% in pre-market trading on rumors it could be the target of several potential suitors, including Biogen . Juno Therapeutics h...

Reversal Offers Chance in 2 Small Biotechs

Reversal Offers Chance in 2 Small Biotechs

I've added to my positions in these names on yesterday's intraday silliness.

Bitcoin, Celgene and Everything Else You Need to Before Wednesday's Opening Bell

Bitcoin, Celgene and Everything Else You Need to Before Wednesday's Opening Bell

Bitcoin maintains its decline while U.S. stock futures suggest a rebound from yesterday's small loss. Are you ready for today's trading?

Celegene, CES and Everything Else You Need to Know Monday in Under 60 Seconds

Celegene, CES and Everything Else You Need to Know Monday in Under 60 Seconds

Are you ready to start the week? Here's what needs to be on your radar.

Some Morning Observations

So far: * Retail is quickly reversing yesterdays strength. Dillard's (-$1.70) and Macy's (-$0.70) downside leaders. * Gold quiet, +$1.90. Though optimistic for the full year I would not chase SPDY Gold ETF GLD at these levels. (I am a buyer on weakn...

Jim Cramer: Stocks Are on Fire For Good Reasons

Jim Cramer: Stocks Are on Fire For Good Reasons

Stocks put in broad gains supported by tax cuts, bonuses, a weaker dollar and more.

Use Caution on Celgene, Going Long Is for the Aggressive and Experienced

Use Caution on Celgene, Going Long Is for the Aggressive and Experienced

This is the kind of activity you see at a climax low.

Celgene Chart Bears Watching

Celgene Chart Bears Watching

Although it appears the low may be in from October, it is hard to trust this stock.

Key Feature in Marketks

The key feature within the markets is the renewed and continued strength in pharma and biotech which started last week. Allergan , Celgene and Gilead Sciences  are upside features. I am not involved and I would not chase big Pharma or biotech.

Mid-Afternoon Observations

Some mid afternoon observations:   * Small yield flattening in today's session and little change in bond yields. * High yield is slipping a bit. * The U.S. Dollar is strengthening after morning weakness. * Oil down after weeks of strength (-$0.76/ba...

Here's What's Up This A.M.

The Nasdaq (QQQs) turn slightly negative as most of the FANGs reverse lower.   Retail, generics (Teva and Mylan ), big pharma (Merck and Bristol-Myers Squibb ) and biotech (Allergan , Gilead Sciences , Celgene ) are conspicuous to the downside.   Co...